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Patients diagnosed with cancer often experience sleep disturbance in the form of poor sleep patterns or insomnia that can start on diagnosis 
and continue until the end of the individual’s life. The aim of this review is to discuss current definitions and theories of sleep disturbance, its 
prevalence, the underlying physiological and psychological correlates, measurement scales, and possible intervention and management strategies. 
Equally important, regular assessment is worthwhile for sleep disturbance and quality of life among cancer patients. Therefore, it is advisable 
for health‑care professionals to conduct regular assessment of sleep disturbance for cancer patients and provide appropriate management.
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INTRODUCTION
Diagnosis of cancer is a major life stressor that can affect 
the physiological, psychological, and physical state of a 
person. The cancer journey can involve pain, weakness, sleep 
problems, and fatigue, and may cause limited function in 
terms of active daily living. People with cancer may experience 
symptoms related to their treatment and/or disease type and 
stage. One of the most common and distressing symptoms 
is sleep disturbance, which negatively affects the quality of 
life.[1] Patients diagnosed with cancer often experience sleep 
disturbance, especially insomnia. Sleep disturbance among 
cancer patients is a familiar problem and can start with the 
diagnosis and continue to the end of the patient’s life.[2,3]
This review will discuss the current definitions and theories 
of sleep disturbance, its prevalence, the underlying 
physiological and psychological correlates, measurement 
scales, and possible intervention and management strategies.
DEFINITIONS OF SLEEP DISTURBANCE
There are potential difficulties in defining sleep disturbance 
or disorder, as sleep quality is a multidimensional concept. 
Buysse[4] defines sleep health as, “a multidimensional pattern 
of sleep-wakefulness, adapted to individual, social, and 
environmental demands, that promotes physical and mental 
well-being.” Good sleep health is characterized by subjective 
satisfaction, appropriate timing, adequate duration, high 
efficiency, and sustained alertness during waking hours.
The National Institute of Health[5] defines sleep disturbance 
as, “dysregulation of sleep homeostasis, sleep deficiency, 
sleep fragmentation, insufficient sleep or impairment 
of sleep quality or quantity caused by a sleep disorder.” 
Specifically, sleep disturbance may include difficulty falling 
asleep, problems with the initiation and maintenance of 
sleep, poor sleep timing, quality, efficiency, and excessive 
daytime sleepiness.[6-8]
The International Classification of Sleep Disorder-3 divides 
sleep symptoms into the following three diagnostic sections: 
insomnia, sleepiness, or abnormal events during sleep.[9] 
Insomnia is a sleep disturbance symptom that has been 
excessively used in the literature to describe sleep symptoms 
Sleep disturbance in patients with cancer






This is an open access journal, and articles are distributed under the terms of the Creative 
Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to 
remix, tweak, and build upon the work non‑commercially, as long as appropriate credit 
is given and the new creations are licensed under the identical terms.
For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com
How to cite this article: Al Maqbali M. Sleep disturbance in patients with 
cancer. J Integr Nurs 2020;2:153-9.
Submitted: 10-Jul-2020 Revised: 10-Aug-2020 
Accepted: 18-Aug-2020 Published: 25-Dec-2020
[Downloaded free from http://www.journalin.org on Friday, September 10, 2021, IP: 10.232.74.23]
Al Maqbali: Sleep disturbance in patients with cancer
154 Journal of Integrative Nursing / Volume 2 / Issue 4 / October-December 2020
among patients diagnosed with cancer. Roth et al.[10] defined 
insomnia as difficulty initiating or maintaining sleep or 
nonrestorative sleep; it is also associated with daytime 
distress or impairment.
Difficulty sleeping is a phrase regularly used by patients 
to describe their sleep. The major challenge facing 
the researcher is to verify what this means and how 
to measure it. The following nine parameters of sleep 
disturbance have been recommended to measure sleep 
problems: total sleep time, sleep latency, awakenings, 
wake time after sleep sunset, napping during the day, 
excessive daytime sleepiness, quality of perceived sleep, 
stability of circadian rhythms, and sleep efficiency.[11] Adult 
parameters of sleep disturbance include sleeping for <7 h, 
sleep latency of >20 min, awakening >7 times during the 
night, waking after sleep onset >10% of the time, napping 
during the daytime for >2 h, minimal opportunities for 
daytime sleepiness while engaging with routine activities, 
satisfaction with the quality of perceived sleep, circadian 
rhythms within a 27 h period, and <80% sleep efficiency 
indicating a bad night.[6]
Sleep disturbance, thus, is a multidimensional concept 
that is, accordingly, measured across multiple aspects 
or dimensions. Understanding the differences between 
normal sleep and poor sleep can help health-care 
professionals in designing interventions to improve sleep, 
through a comprehensive care plan that meets the needs 
of patients with cancer. Defining sleep disturbance will, 
thus, guide the researcher and promote the health of 
such patients.
PREVALENCE OF SLEEP DISTURBANCE
Sleep disturbance is reported to be the second most 
common symptom among cancer patients.[12] Identifying the 
prevalence of sleep disturbance is important in understanding 
the underlying problem and developing treatment or a 
particular intervention for patients with cancer. A systematic 
review by Otte et al.[13] found that the prevalence for specific 
types of sleep disturbance in cancer remains unclear.
Sleep disturbance prevalence, type, and severity are difficult 
to assess in patients diagnosed with cancer, with incidences 
ranging from 50%[11] to 88%.[14] This is approximately three 
times higher than the rate within the general population.[15] 
Differences in prevalence among cancer patient populations 
may be partially dependent on cancer types, stages, and time 
of measurement such as pre- or post-chemotherapy/pre- or 
post-radiotherapy.
In a recent study, Akman et al.[16] examined the prevalence 
of sleep disturbance in 314 patients with different types of 
cancer; these researchers found 40.4% of patients suffered 
from poor quality sleep. An integrative review of 27 studies 
evaluating sleep quality in women with breast cancer 
found that the prevalence of sleep disturbance ranged 
from 65% to 87%.[17] In a large population-based study, Voiss 
et al.[18] reported sleep problems from the 2017 US National 
Health Interview Survey of 23,222,976 cancer survivors 
and found that 59.2% reported sleep problem. Al Maqbali 
et al.[19] conducted a cross-sectional study to identify sleep 
disturbance in 369 cancer survivors and found that the 
prevalence of poorer sleep among participants was 78%. 
A prospective study of 73 patients with breast cancer reported 
that 97% of patients experienced poor-quality sleep.[20]
Different types of cancer can lead to different percentages of 
patients experiencing sleep disturbance; for example, thyroid, 
54.32%;[21] lung, 93.1%;[22] head and neck, 83%;[23] leukemia, 
67.5%;[24] and melanoma, 60.7%.[25] Savard et al.[26] conducted 
a longitudinal study of patients with breast (n = 465) and 
prostate (n = 263) cancer to evaluate the relationship 
between adjuvant treatment and insomnia. They found that 
for breast cancer patients, insomnia was 66.2% at baseline, 
51% at 6 months, and 38.8% at 18 months, whereas for 
prostate cancer patients, insomnia was 36.9% at baseline, 
29% at 6 months, and 25% at 18 months.
Sleep disturbance may occur during the treatment of cancer, 
before and after surgical interventions, during radiotherapy 
and/or chemotherapy, and even after completing treatment. 
A longitudinal study by Halle et al.[27] explored sleep 
disturbance in 264 lung cancer patients who had undergone 
surgery and found that sleep disturbance was 60.9% at 
baseline, 68.5% at 1 month, 55.4% at 5 months, and 49.7% 
at 9 months.
Hong et al.[28] assessed sleep disturbance every 4th week 
during chemotherapy treatment for 706 patients with 
mixed types of cancer. They found that sleep quality was 
51.86% at baseline and 68.54%, 83.48%, 89.36%, and 96.43% 
every 4th week, showing an increase in sleep disturbance 
during chemotherapy treatment. An observational study 
conducted by Tian et al.[29] involving 76 cervical cancer 
patients undergoing chemotherapy found that sleep quality 
was 61.84% before and 64.50% after adjuvant therapy.
Radiotherapy is a primary form of treatment for cancer 
patients. A prospective study by Mo et al.[30] investigated sleep 
changes before and after radiotherapy for 51 nasopharyngeal 
cancer patients; the results showed that 37.3% of patients 
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had poor sleep quality before starting radiotherapy, which 
increased to 64.7% after radiotherapy. Similarly, a longitudinal 
study of eighty breast cancer patients found that poor sleep 
before, during, and after radiotherapy was 61%, 56%, and 
59%, respectively.[31]
Sleep disturbance may increase even after completing 
treatment. For instance, Lowery-Allison et al.’s[32] study of 
breast cancer survivors, 1–10 years posttreatment, found 
that 38% (76 out of 200) of patients experienced poor quality 
sleep. Findings from a cross-sectional survey of 337 cancer 
survivors by Ness et al.[33] found that 50% of participants 
reported sleep disturbance.
A systematic review of 254 studies by Otte et al.[13] found that 
the prevalence of sleep disorders could not be ascertained from 
research on patients with cancer. This was primarily due to 
the conceptualization and operationalization of “poor sleep,” 
as the studies used different terminology that did not fully 
assess sleep disorder; thus, most of the studies (89.8%; 228) 
did not define sleep disorders. A cross-sectional study in 
South Korea by Park et al.,[34] of 30,400 patients diagnosed 
with cancer, found the prevalence of insomnia to be 8.21%; 
this was highest among lung cancer patients. However, the 
study did not use an instrument to measure insomnia, which 
means the percentage only reflects patients diagnosed with 
insomnia. Sleep disturbance can be assessed using objective 
measures and through self-reports. Wrist actigraphy is one 
such objective measure; however, many researchers have used 
a self-report instrument to measure sleep disturbance. The 
different findings between the studies reported above could 
be due to the variety of assessment methods used.
Consequently, understating the level of poor sleep among 
patients with cancer before, during, and after treatment is 
an important research area that will help in the development 
of an intervention for specific types of cancer and different 
stages of the cancer patient journey. However, as this review 
of the literature shows, it is important to use a valid and 
standard method of assessing “poor sleep”.
IMPACT OF SLEEP DISTURBANCE
Sleep disorders are reported to be associated with decreased 
quality of life, increased use of health-care resources, and poor 
mood. Sleep disturbance has also been linked with the likelihood 
of cancer recurrence[35,36] and may result in poor healing,[13] 
decreased cognitive functioning,[37] and reduced work activity.[38]
Evidence of sleep disturbance impact is provided by 
surveys from the USA and five European countries, which 
found that people with insomnia experienced significantly 
worse health-related quality of life compared to people 
with normal sleep.[39] Sleep disturbance can cause changes 
in metabolism,[40] immune pathways,[41] and endocrine 
functioning.[42] Similarly, sleep disturbance in cancer patients 
can have a negative impact on health-related quality of life, 
which includes physical and psychological functioning.[43,44]
Research indicates that sleep disorders or poor sleep can 
have other negative effects on health, insofar as it can 
significantly increase the risk of developing Type 2 diabetes[45] 
and hypertension[46] and increase the risk of cardiovascular 
disease.[47] However, it is important to note that the 
consequences of sleep disorders are not confined to the 
individual; they may also have implications at a societal level 
in terms of public health and economic burdens.[48]
ETIOLOGY AND INFLUENCIAL FACTORS OF SLEEP 
DISTURBANCE
Sleep disturbance in patients with cancer may be attributable 
to the physiological and psychological effects of the cancer 
and the effects of treatment, surgery, chemotherapy, 
radiotherapy, and medications. Thus, it is difficult to establish 
the etiology of sleep disturbance.
In terms of demographic factors, being female, older age, having 
a lower level of education, and engaging in less physical activity 
have all been linked to sleep disturbance.[49-51] In a cross-sectional 
study of 209 mixed cancer patients, Akechi et al.[52] found a 
significant relationship between sleep disturbance and younger 
age, marital status (unmarried), living alone, higher psychological 
distress, pain, and diarrhea. However, the age relationship 
may be influenced by other factors that could increase sleep 
disturbance. For instance, Coles et al.[53] found that pain, anxiety, 
fatigue, and multiple comorbid conditions were significantly 
associated with worsening sleep disturbance among colorectal 
cancer patients. Galiano-Castillo et al.[54] also found a significant 
relationship between insomnia and types of treatment, 
depression, and anxiety among breast cancer patients.
In the context of cancer, tumor type and the treatments 
used may influence sleep disturbance. For example, Savard 
et al.[55] conducted a longitudinal study of 962 mixed patients 
over 18 months and found a significant association between 
insomnia and different types of cancer, including breast, 
prostate, gynecologic, urinary, and gastro-intestinal cancer. 
Furthermore, studies conducted on cancer patients to 
assess treatment efficacy found that chemotherapy[56] and 
radiotherapy[57] were significantly associated with an increase 
in sleep disturbance.
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Furthermore, chemotherapy and radiotherapy have been 
associated with an increase in sleep disturbance and 
the level of pro-inflammatory cytokine markers such as 
interleukin (IL)-1β and IL-6 and tumor necrosis factor-α.[58-60] 
Current evidence shows that immune mediators are released 
as a response to pathogen invasion tissue injury or cytotoxic 
factors.[61] Even though some studies have found a relationship 
between cytokine markers and sleep disturbance, this is still 
not fully understood and further research is required in this 
area. Cancer-induced changes in metabolism, immunity, or 
endocrine function likely disrupt sleep via the promotion of 
aberrant activity within some neural populations.[62]
Overall, research findings suggest that sleep disturbance is 
associated with several different factors, but these factors 
will change from patient to patient. Further research should, 
therefore, explore these factors to facilitate their appropriate 
management and develop a strategy to prevent or reduce 
sleep disturbance.
MEASUREMENT OF SLEEP DISTURBANCE
Sleep disturbance can be assessed either objectively or 
subjectively. The two most common objective measurements 
for patients with cancer are polysomnography (PSG) and 
actigraphy, whereas the following three subjective scales have 
been used and validated in cancer populations: the Pittsburgh 
Sleep Quality Index (PSQI), Epworth Sleepiness Scales (ESS), 
and the Insomnia Severity Index (ISI). However, each of the 
assessment methods has both advantages and disadvantages.
Objective measures
PSG is the gold standard for recording sleep.[63,64] The 
components of PSG consist of electroencephalography, 
electrocardiogram, electrooculography, electromyography, 
arterial oxygen saturation, respiratory effort, oral and nasal 
airflow, body position, and limb movement.[65] The data 
derived from PSG involve sleep latency, wake after sleep 
onset time, total sleep time, and sleep efficiency. However, 
PSG is expensive and does not provide information about 
sleep habits at home.
Actigraphy involves wearing a wrist device that measures 
movement activity between sleep and awake states.[66] The 
advantages of actigraphy are that it is easy to use, it is cheaper 
than PSG, and it can record for 24 h for a month.
Subjective measures
The PSQI is a 19-item scale designed to measure different 
aspects of sleep quality and sleep disturbance.[67] The scale 
reports the sleep quality of the previous month. The PSQI 
is divided into seven subscale scores, namely, subjective 
sleep quality, sleep latency (time to full sleep), duration, 
habitual sleep efficiency (proportion between total sleep 
time and time in bed), sleep disturbances (waking up 
during the night), use of sleeping medication, and daytime 
dysfunction (difficulty staying awake during daytime). The 
overall score ranges between 0 and 21; the high score 
indicates poor sleep quality. The original PSQI was tested 
on both psychiatric patients and a healthy sample; however, 
it has been validated in different clinical populations. Two 
studies have validated the PSQI in patients with cancer and 
showed internal consistency (Cronbach’s alpha = 0.89).[68,69]
The ESS was constructed to assess daytime sleepiness and 
diagnose sleep disorders across eight items in a 4-point Likert 
scale.[70] The total score ranges between 0 (normal sleep) and 
24 (very sleepy).
The ISI has seven items on a 5-point Likert scale; it has 
three subscales assessing the nature, severity, and impact 
of insomnia.[71] The scale measures the interval in the last 
2 weeks. The overall score ranges between 0 and 28; the 
higher score indicates more severe insomnia. The total score 
can be categorized as follows: 0–7 (absence of insomnia); 
8–14 (subthreshold insomnia); 15–24 (moderate insomnia); 
and 22–28 (severe insomnia).
All subjective measures are easy to administer and cheap, 
however they cannot roll out the subjective recall biases.[72] 
Consideration should be given when choosing an appropriate 
instrument of measuring sleep quality for research or clinical 
proposes, as each objective or subjective measure has 
advantages and disadvantages.
MANAGEMENT OF SLEEP DISTURBANCE
The management of sleep disturbance has involved a range 
of interventions that can be divided into pharmacological 
and nonpharmacological approaches. Several studies have 
investigated the effectiveness of nonpharmacological 
interventions on sleep disturbance in cancer patients, 
whereas no pharmacological interventions have been 
included in studies involving cancer patients. For example, 
cognitive behavioral interventions (CBIs) have had significant 
effects on reducing sleep disturbance, with several reviews 
recommending their use.[73,74] CBIs include sleep hygiene, 
stimulator control, relaxation therapies, sleep restriction, 
and cognitive restructuring. In a meta-analysis of nine 
studies, Johnson et al.[74] found that CBIs lead to reductions 
in insomnia, sleep-onset latency, and improved sleep 
efficiency in cancer survivors. A randomized controlled 
trial of 248 patients with breast cancer was undertaken by 
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Savard et al.[75] who found that CBIs had a significant effect 
on insomnia at a 12-month follow-up.
In a study by Reich et al.[76] involving 320 breast cancer 
patients, a mindfulness-based stress reduction (MBSR) was 
applied for 12 weeks; it had a significant effect on sleep 
quality. This result was supported by a randomized controlled 
trial evaluating the effectiveness of MBSR among breast and 
colorectal cancer patients, which also showed a significant 
reduction in sleep disturbance.[77,78]
Other mind–body practices focusing on the interaction 
between the brain, mind, body, and behavior, have 
demonstrated an improvement in sleep disturbance, 
such as yoga;[79] warm shower or baths;[80] acupuncture;[81] 
Qi Gong/Tai Chi;[82] and massage.[83]
Exercise interventions to reduce sleep disturbance 
among cancer patients have been undertaken and 
reported in several reviews. However, the evidence was 
inconclusive due to biases in several studies. In a recent 
systematic review and meta-analysis of 17 randomized 
controlled trials (RCTs) and four non-RCTs involving a 
total of 1595 participants, Mercier et al.[84] concluded that 
exercise interventions have no significant effect on sleep 
outcomes in patients with cancer. However, in comparison, 
a systematic review by Chiu et al.[85] of nine RCTs involving 
599 patients found a modest effect of walking exercise on 
reducing sleep disturbance.
A number of clinical practice guidelines have been 
published for pharmacological management of the 
general population. For example, the American Academy 
of Sleep Medicine (AASM) conducted a meta-analysis of 
46 studies and found weak evidence to support the use of 
14 agents (suvorexant, eszopiclone, zaleplon, zolpidem, 
triazolam, temazepam, ramelteon, doxepin, trazodone, 
tiagabine, diphenhydramine, melatonin, tryptophan, and 
valerian).[86] The AASM guidelines concluded that these 
agents are not recommended for the treatment of chronic 
insomnia in adults.
To conclude, the Oncology Nursing Society published 
guidelines that critically appraised evidence for the safety and 
efficacy of using pharmacological and nonpharmacological 
interventions to reduce sleep disturbance in patients with 
cancer.[87] The guidelines found sufficient evidence to use 
CBIs, while MBSR and exercise intervention were likely to 
be effective, but required further research. Research on 
pharmacological interventions in cancer populations has yet 
to be conducted.
CONCLUSION
Sleep disturbance is a multidimensional concept whose 
prevalence and severity is higher among patients with cancer. 
The impact of sleep disturbance has been linked to the 
recurrence of cancer and a reduced life span among cancer 
survivors. This review has provided important evidence for 
measuring and managing sleep disturbance that can help 
in understanding sleep disturbance among cancer patients. 
Assessing sleep disturbance should be routine in clinical 
settings, thus identifying proper interventions, treatment, and 
management to improve sleep quality among cancer patients.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
REFERENCES
1. Wu HS, Harden JK. Symptom burden and quality of life in survivorship: 
A review of the literature. Cancer Nurs 2015;38:E29‑54.
2. Berger AM. Update on the state of the science: Sleep‑wake disturbances 
in adult patients with cancer. Oncol Nurs Forum 2009;36:E165‑77.
3. Otte JL, Carpenter JS, Russell KM, et al. Prevalence, severity, and 
correlates of sleep‑wake disturbances in long‑term breast cancer 
survivors. J Pain Symptom Manage 2010;39:535‑47.
4. Buysse DJ. Sleep health: Can we define it? Does it matter? Sleep 
2014;37:9‑17.
5. National Institutes of Health. National Institutes of Health Sleep 
Disorders Research Plan. Maryland, USA: National Institutes of Health; 
2011. p. 1‑34.
6. Berger AM, Matthews EE, Aloia MS. Sleep and cancer. In: Olver I, 
editor. MASCC Textb Cancer Support Care Surviv. Cham: Springer 
International Publishing; 2018. p. 53‑65.
7. Otte JL, Davis L, Carpenter JS, et al. Sleep disorders in breast cancer 
survivors. Support Care Cancer 2016;24:4197‑205.
8. Sateia MJ. International classification of sleep disorders‑third edition: 
Highlights and modifications. Chest 2014;146:1387‑94.
9. American Academy of Sleep Medicine. International classification of 
sleep disorders–third edition (ICSD‑3). 3rd ed. Darien, IL: American 
Academy of Sleep Medicine; 2014.
10. Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health 
associated with insomnia based on DSM‑IV‑TR; International Statistical 
Classification of Diseases and Related Health Problems, Tenth Revision; 
and Research Diagnostic Criteria/International Classification of Sleep 
Disorders, Second Edition criteria: Results from the America Insomnia 
Survey. Biol Psychiatry 2011;69:592‑600.
11. Berger AM, Parker KP, Young‑McCaughan S, et al. Sleep wake 
disturbances in people with cancer and their caregivers: State of the 
science. Oncol Nurs Forum 2005;32:E98‑126.
12. Cleeland CS, Zhao F, Chang VT, et al. The symptom burden of cancer: 
Evidence for a core set of cancer‑related and treatment‑related symptoms 
from the Eastern Cooperative Oncology Group Symptom Outcomes and 
Practice Patterns study. Cancer 2013;119:4333‑40.
13. Otte JL, Carpenter JS, Manchanda S, et al. Systematic review of sleep 
disorders in cancer patients: Can the prevalence of sleep disorders be 
ascertained? Cancer Med 2015;4:183‑200.
[Downloaded free from http://www.journalin.org on Friday, September 10, 2021, IP: 10.232.74.23]
Al Maqbali: Sleep disturbance in patients with cancer
158 Journal of Integrative Nursing / Volume 2 / Issue 4 / October-December 2020
14. Clark J, Cunningham M, McMillan S, et al. Sleep‑wake disturbances in 
people with cancer part II: Evaluating the evidence for clinical decision 
making. Oncol Nurs Forum 2004;31:747‑71.
15. Heinzer R, Vat S, Marques‑Vidal P, et al. Prevalence of sleep‑disordered 
breathing in the general population: The HypnoLaus study. Lancet Respir 
Med 2015;3:310‑8.
16. Akman T, Yavuzsen T, Sevgen Z, et al. Evaluation of sleep disorders in 
cancer patients based on Pittsburgh Sleep Quality Index. Eur J Cancer 
Care (Engl) 2015;24:553‑9.
17. Mansano‑Schlosser TC, Ceolim MF, Valerio TD. Sleep quality in women 
with breast cancer: An integrative review. Int Arch Med 2016;9:1‑17.
18. Voiss P, Höxtermann MD, Dobos G, et al. Cancer, sleep problems, and 
mind‑body medicine use: Results of the 2017 National Health Interview 
Survey. Cancer 2019;125:4490‑7.
19. Al Maqbali M, Hughes C, Rankin J, et al. Fatigue and sleep disturbance 
in Arabic cancer patients after completion of therapy: Prevalence, 
correlates, and association with quality of life. Cancer Nurs 2020; https://
doi.org/10.1097/ncc.0000000000000825.
20. Dhruva A, Paul SM, Cooper BA, et al. A longitudinal study of measures 
of objective and subjective sleep disturbance in patients with breast 
cancer before, during, and after radiation therapy. J Pain Symptom 
Manage 2012;44:215‑28.
21. He Y, Meng Z, Jia Q, et al. Sleep quality of patients with differentiated 
thyroid cancer. PLoS One 2015;10:e0130634.
22. Lin S, Chen Y, Yang L, et al. Pain, fatigue, disturbed sleep and distress 
comprised a symptom cluster that related to quality of life and functional 
status of lung cancer surgery patients. J Clin Nurs 2013;22:1281‑90.
23. Li N, Otomaru T, Taniguchi H. Sleep quality in long‑term survivors 
of head and neck cancer: Preliminary findings. Support Care Cancer 
2017;25:3741‑8.
24. Miladinia M, Baraz S, Ramezani M, et al. The relationship between 
pain, fatigue, sleep disorders and quality of life in adult patients with 
acute leukaemia: During the first year after diagnosis. Eur J Cancer 
Care (Engl) 2018;27:e12762. https://doi.org/10.1111/ecc.12762.
25. Martinez‑Garcia MA, Martorell A, Nagore E, et al. Relationship Between 
Sleep‑Disordered Breathing And Aggressiveness Markers Of Malignant 
Cutaneous Melanoma. A Multicentric Study. B99 Best Everything Hot 
Top Sleep. American Thoracic Society; 2016. p. A4323.
26. Savard J, Ivers H, Savard MH, et al. Cancer treatments and their 
side effects are associated with aggravation of insomnia: Results of a 
longitudinal study. Cancer 2015;121:1703‑11.
27. Halle IH, Westgaard TK, Wahba A, et al. Trajectory of sleep disturbances 
in patients undergoing lung cancer surgery: A prospective study. Interact 
Cardiovasc Thorac Surg 2017;25:285‑91.
28. Hong JS, Tian J, Wu LH. The influence of chemotherapy‑induced 
neurotoxicity on psychological distress and sleep disturbance in cancer 
patients. Curr Oncol 2014;21:174‑80.
29. Tian J, Chen GL, Zhang HR. Sleep status of cervical cancer patients 
and predictors of poor sleep quality during adjuvant therapy. Support 
Care Cancer 2015;23:1401‑8.
30. Mo YL, Li L, Qin L, et al. Cognitive function, mood, and sleep 
quality in patients treated with intensity‑modulated radiation therapy 
for nasopharyngeal cancer: A prospective study. Psychooncology 
2014;23:1185‑91.
31. Hanasoge S, Wang X, Chen Z, et al. The influence of radiotherapy 
on sleep disturbances in breast cancer patients. J Clin Oncol 
2014;32:1092‑2.
32. Lowery‑Allison AE, Passik SD, Cribbet MR, et al. Sleep problems in 
breast cancer survivors 1‑10 years posttreatment. Palliat Support Care 
2018;16:325‑34.
33. Ness S, Kokal J, Fee‑Schroeder K, et al. Concerns across the survivorship 
trajectory: Results from a survey of cancer survivors. Oncol Nurs Forum 
2013;40:35‑42.
34. Park B, Youn S, Hann CW, et al. Prevalence of insomnia among patients 
with the ten most common cancers in South Korea: Health insurance 
review and assessment service‑national patient sample. Sleep Med Res 
2016;7:48‑54.
35. Sigurdardottir LG, Valdimarsdottir UA, Mucci LA, et al. Sleep disruption 
among older men and risk of prostate cancer. Cancer Epidemiol 
Biomarkers Prev 2013;22:872‑9.
36. Thompson CL, Li L. Association of sleep duration and breast 
cancer OncotypeDX recurrence score. Breast Cancer Res Treat 
2012;134:1291‑5.
37. Schagen SB, Klein M, Reijneveld JC, et al. Monitoring and optimising 
cognitive function in cancer patients: Present knowledge and future 
directions. EJC Suppl 2014;12:29‑40.
38. Die Trill M. Anxiety and sleep disorders in cancer patients. EJC 
Suppl 2013;11:216‑24.
39. DiBonaventura M, Richard L, Kumar M, et al. The association between 
insomnia and insomnia treatment side effects on health status, work 
productivity, and healthcare resource use. PLoS One 2015;10:e0137117.
40. Zimberg IZ, Dâmaso A, Del Re M, et al. Short sleep duration and 
obesity: Mechanisms and future perspectives. Cell Biochem Funct 
2012;30:524‑9.
41. Besedovsky L, Lange T, Born J. Sleep and immune function. Pflugers 
Arch 2012;463:121‑37.
42. Morgan D, Tsai SC. Sleep and the endocrine system. Crit Care Clin 
2015;31:403‑18.
43. Palesh OG, Roscoe JA, Mustian KM, et al. Prevalence, demographics, 
and psychological associations of sleep disruption in patients with 
cancer: University of Rochester Cancer Center‑Community Clinical 
Oncology Program. J Clin Oncol 2010;28:292‑8.
44. Rolke HB, Bakke PS, Gallefoss F. HRQoL changes, mood disorders 
and satisfaction after treatment in an unselected population of patients 
with lung cancer. Clin Respir J 2010;4:168‑75.
45. Holliday EG, Magee CA, Kritharides L, et al. Short sleep duration is 
associated with risk of future diabetes but not cardiovascular disease: 
A prospective study and meta‑analysis. PLOS ONE 2013;8:e82305.
46. Anothaisintawee T, Reutrakul S, Van Cauter E, et al. Sleep disturbances 
compared to traditional risk factors for diabetes development: Systematic 
review and meta‑analysis. Sleep Med Rev 2016;30:11‑24.
47. Khan MS, Aouad R. The effects of insomnia and sleep loss on 
cardiovascular disease. Sleep Med Clin 2017;12:167‑77.
48. Colten HR, Altevogt BM. Sleep Disorders and Sleep Deprivation: 
An Unmet Public Health Problem. Washington, D.C.: The National 
Academies Press; 2006.
49. Colagiuri B, Christensen S, Jensen AB, et al. Prevalence and predictors 
of sleep difficulty in a national cohort of women with primary breast 
cancer three to four months postsurgery. J Pain Symptom Manage 
2011;42:710‑20.
50. Morris BA, Thorndike FP, Ritterband LM, et al. Sleep disturbance 
in cancer patients and caregivers who contact telephone‑based help 
services. Support Care Cancer 2015;23:1113‑20.
51. Nelson AM, Jim HS, Small BJ, et al. Sleep disruption among cancer 
patients following autologous hematopoietic cell transplantation. Bone 
Marrow Transplant 2018;53:307‑14.
52. Akechi T, Okuyama T, Akizuki N, et al. Associated and predictive 
factors of sleep disturbance in advanced cancer patients. Psychooncology 
2007;16:888‑94.
53. Coles T, Tan X, Bennett AV, et al. Sleep quality in individuals diagnosed 
with colorectal cancer: Factors associated with sleep disturbance as 
patients transition off treatment. Psychooncology 2018;27:1050‑6.
54. Galiano‑Castillo N, Arroyo‑Morales M, Ariza‑Garcia A, et al. Factors 
that explain the cancer‑related insomnia. Breast J 2017;23:387‑94.
55. Savard J, Ivers H, Villa J, et al. Natural course of insomnia comorbid with 
cancer: An 18‑month longitudinal study. J Clin Oncol 2011;29:3580‑6.
56. Hsu HT, Lin KC, Wu LM, et al. Symptom cluster trajectories during 
chemotherapy in breast cancer outpatients. J Pain Symptom Manage 
[Downloaded free from http://www.journalin.org on Friday, September 10, 2021, IP: 10.232.74.23]
Al Maqbali: Sleep disturbance in patients with cancer
159Journal of Integrative Nursing / Volume 2 / Issue 4 / October-December 2020
2017;53:1017‑25.
57. López E, de la Torre‑Luque A, Lazo A, et al. Assessment of sleep 
disturbances in patients with cancer: Cross‑sectional study in a 
radiotherapy department. Eur J Oncol Nurs 2016;20:71‑6.
58. Holliday EB, Dieckmann NF, McDonald TL, et al. Relationship between 
fatigue, sleep quality and inflammatory cytokines during external beam 
radiation therapy for prostate cancer: A prospective study. Radiother 
Oncol 2016;118:105‑11.
59. Kwekkeboom KL, Tostrud L, Costanzo E, et al. The role of inflammation 
in the pain, fatigue, and sleep disturbance symptom cluster in advanced 
cancer. J Pain Symptom Manage 2018;55:1286‑95.
60. Steel JL, Terhorst L, Collins KP, et al. Prospective analyses of cytokine 
mediation of sleep and survival in the context of advanced cancer. 
Psychosom Med 2018;80:483‑91.
61. Palesh O, Aldridge‑Gerry A, Ulusakarya A, et al. Sleep disruption in breast 
cancer patients and survivors. J Natl Compr Canc Netw 2013;11:1523‑30.
62. Walker WH 2nd, Borniger JC. Molecular mechanisms of cancer‑induced 
sleep disruption. Int J Mol Sci 2019;20:2780. https://doi.org/10.3390/
ijms20112780.
63. Conley S, Knies A, Batten J, et al. Agreement between actigraphic and 
polysomnographic measures of sleep in adults with and without chronic 
conditions: A systematic review and meta‑analysis. Sleep Med Rev 
2019;46:151‑60.
64. Scott H, Lack L, Lovato N. A systematic review of the accuracy of 
sleep wearable devices for estimating sleep onset. Sleep Med Rev 
2020;49:101227.
65. George CF. Standards for polysomnography in Canada. The standards 
committees of the Canadian Sleep Society and the Canadian Thoracic 
Society. CMAJ 1996;155:1673‑8.
66. Acebo C, LeBourgeois MK. Actigraphy. Respir Care Clin N Am 
2006;12:23‑30, viii.
67. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep 
Quality Index: A new instrument for psychiatric practice and research. 
Psychiatry Res 1989;28:193‑213.
68. Beck SL, Schwartz AL, Towsley G, et al. Psychometric evaluation of 
the Pittsburgh Sleep Quality Index in cancer patients. J Pain Symptom 
Manage 2004;27:140‑8.
69. Otte JL, Payne JK, Carpenter JS. Nighttime variability in wrist 
actigraphy. J Nurs Meas 2011;19:105‑14.
70. Johns MW. A new method for measuring daytime sleepiness: The 
Epworth sleepiness scale. Sleep 1991;14:540‑5.
71. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia 
Severity Index as an outcome measure for insomnia research. Sleep 
Med 2001;2:297‑307.
72. Ibáñez V, Silva J, Cauli O. A survey on sleep questionnaires and diaries. 
Sleep Med 2018;42:90‑6.
73. Garland SN, Xie SX, Li Q, et al. Comparative effectiveness of 
electro‑acupuncture versus gabapentin for sleep disturbances in breast cancer 
survivors with hot flashes: A randomized trial. Menopause 2017;24:517‑23.
74. Johnson JA, Rash JA, Campbell TS, et al. A systematic review and 
meta‑analysis of randomized controlled trials of cognitive behavior 
therapy for insomnia (CBT‑I) in cancer survivors. Sleep Med Rev 
2016;27:20‑8.
75. Savard J, Ivers H, Savard MH, et al. Long‑term effects of two formats of 
cognitive behavioral therapy for insomnia comorbid with breast cancer. 
Sleep 2016;39:813‑23.
76. Reich RR, Lengacher CA, Alinat CB, et al. Mindfulness‑based stress 
reduction in post‑treatment breast cancer patients: Immediate and 
sustained effects across multiple symptom clusters. J Pain Symptom 
Manage 2017;53:85‑95.
77. Johns SA, Brown LF, Beck‑Coon K, et al. Randomized controlled 
pilot trial of mindfulness‑based stress reduction compared to 
psychoeducational support for persistently fatigued breast and colorectal 
cancer survivors. Support Care Cancer 2016;24:4085‑96.
78. Haller H, Winkler MM, Klose P, et al. Mindfulness‑based interventions 
for women with breast cancer: An updated systematic review and 
meta‑analysis. Acta Oncol 2017;56:1665‑76.
79. Cramer H, Lauche R, Klose P, et al. Yoga for improving health‑related 
quality of life, mental health and cancer‑related symptoms in 
women diagnosed with breast cancer. Cochrane Database Syst Rev 
2017;1:CD010802.
80. Haghayegh S, Khoshnevis S, Smolensky MH, et al. Before‑bedtime 
passive body heating by warm shower or bath to improve sleep: 
A systematic review and meta‑analysis. Sleep Med Rev 2019;46:124‑35.
81. Choi TY, Kim JI, Lim HJ, et al. Acupuncture for managing cancer‑related 
insomnia: A systematic review of randomized clinical trials. Integr 
Cancer Ther 2017;16:135‑46.
82. Wayne PM, Lee MS, Novakowski J, et al. Tai Chi and Qigong for 
cancer‑related symptoms and quality of life: A systematic review and 
meta‑analysis. J Cancer Surviv 2018;12:256‑67.
83. Kashani F, Kashani P. The effect of massage therapy on the quality of 
sleep in breast cancer patients. Iran J Nurs Midwifery Res 2014;19:113‑8.
84. Mercier J, Savard J, Bernard P. Exercise interventions to improve sleep 
in cancer patients: A systematic review and meta‑analysis. Sleep Med 
Rev 2017;36:43‑56.
85. Chiu HY, Huang HC, Chen PY, et al. Walking improves sleep in 
individuals with cancer: A meta‑analysis of randomized, controlled 
trials. Oncol Nurs Forum 2015;42:E54‑62.
86. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for 
the pharmacologic treatment of chronic insomnia in adults: An American 
Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep 
Med 2017;13:307‑49.
87. Matthews E, Carter P, Page M, et al. Sleep‑wake disturbance: 
A systematic review of evidence‑based interventions for management 
in patients with cancer. Clin J Oncol Nurs 2018;22:37‑52.
[Downloaded free from http://www.journalin.org on Friday, September 10, 2021, IP: 10.232.74.23]
